ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2
Latest Publications

TOTAL DOCUMENTS

(FIVE YEARS 0)

H-INDEX

(FIVE YEARS 0)

Published By American Chemical Society

9780841234321, 9780841234314

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.ch006 ◽

2019 ◽

pp. 125-154 ◽

Cited By ~ 1

Author(s):

Neil F. Langille ◽

Daniel B. Horne

Subject Index

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.ix002 ◽

2019 ◽

pp. 329-336

Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.ch009 ◽

2019 ◽

pp. 239-266

Author(s):

James J. Crawford ◽

Haiming Zhang

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Kinase Inhibitor ◽

Bruton’S Tyrosine Kinase ◽

Bruton's Tyrosine Kinase

From Discovery to Market Readiness: The Research and Development of the β-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.ch003 ◽

2019 ◽

pp. 61-83

Author(s):

Rémy Angelaud ◽

Steve Staben ◽

Timothy Heffron ◽

Andreas Schuster ◽

Frédéric St-Jean

Keyword(s):

Research And Development ◽

Kinase Inhibitor ◽

Phosphatidylinositol 3 Kinase ◽

Phosphatidylinositol 3

The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.ch005 ◽

2019 ◽

pp. 107-123

Author(s):

Andreas Stumpf ◽

Daniel Sutherlin ◽

Christoph M. Dehnhardt ◽

Rémy Angelaud

Keyword(s):

Large Scale ◽

Large Scale Synthesis

Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.ch011 ◽

2019 ◽

pp. 297-322

Author(s):

Andrew J. Peat ◽

Shiping Xie

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Virus Infection ◽

Rational Design ◽

Large Scale ◽

Hepatitis C Virus Infection ◽

Large Scale Synthesis

Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.ch002 ◽

2019 ◽

pp. 27-59 ◽

Cited By ~ 1

Author(s):

Robert Dugger ◽

Bryan Li ◽

Paul Richardson

Synthetic Routes for Venetoclax at Different Stages of Development

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.ch001 ◽

2019 ◽

pp. 1-25

Author(s):

Yi-Yin Ku ◽

Michael D. Wendt

Keyword(s):

Stages Of Development ◽

Synthetic Routes

Preface

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.pr002 ◽

2019 ◽

pp. xi-xiv

Author(s):

Jaan A. Pesti ◽

Ahmed F. Abdel-Magid ◽

Rajappa Vaidyanathan

Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2 ◽

10.1021/bk-2019-1332.ch008 ◽

2019 ◽

pp. 185-238

Author(s):

Christian Harcken ◽

Joshuaine Grant ◽

Hossein Razavi ◽

Maurice A. Marsini ◽

Frederic G. Buono ◽

...

Keyword(s):

Flow Synthesis

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2Latest Publications

TOTAL DOCUMENTS

H-INDEX

Published By American Chemical Society

Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine

Subject Index

Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853)

From Discovery to Market Readiness: The Research and Development of the β-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib

The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis

Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection

Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC

Synthetic Routes for Venetoclax at Different Stages of Development

Preface

Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis

ACS Symposium Series - Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 2
Latest Publications